vs

Side-by-side financial comparison of BrightSpire Capital, Inc. (BRSP) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Zai Lab Ltd is the larger business by last-quarter revenue ($127.1M vs $83.2M, roughly 1.5× BrightSpire Capital, Inc.). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -0.4%). BrightSpire Capital, Inc. produced more free cash flow last quarter ($55.1M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs -6.8%).

Oakley Capital Investments, is a large British investment trust focused on investments in mid-market companies in the business services, consumer, education and technology sectors. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

BRSP vs ZLAB — Head-to-Head

Bigger by revenue
ZLAB
ZLAB
1.5× larger
ZLAB
$127.1M
$83.2M
BRSP
Growing faster (revenue YoY)
ZLAB
ZLAB
+17.5% gap
ZLAB
17.1%
-0.4%
BRSP
More free cash flow
BRSP
BRSP
$81.8M more FCF
BRSP
$55.1M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
-6.8%
BRSP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BRSP
BRSP
ZLAB
ZLAB
Revenue
$83.2M
$127.1M
Net Profit
$-14.4M
Gross Margin
51.0%
Operating Margin
-54.6%
Net Margin
-17.3%
Revenue YoY
-0.4%
17.1%
Net Profit YoY
27.3%
EPS (diluted)
$-0.11
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BRSP
BRSP
ZLAB
ZLAB
Q4 25
$83.2M
$127.1M
Q3 25
$83.9M
$115.4M
Q2 25
$85.9M
$109.1M
Q1 25
$77.6M
$105.7M
Q4 24
$83.5M
$108.5M
Q3 24
$88.2M
$101.8M
Q2 24
$91.4M
$100.1M
Q1 24
$95.8M
$87.1M
Net Profit
BRSP
BRSP
ZLAB
ZLAB
Q4 25
$-14.4M
Q3 25
$984.0K
$-36.0M
Q2 25
$-23.1M
$-40.7M
Q1 25
$5.3M
$-48.4M
Q4 24
$-19.7M
Q3 24
$12.7M
$-41.7M
Q2 24
$-67.9M
$-80.3M
Q1 24
$-57.1M
$-53.5M
Gross Margin
BRSP
BRSP
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
BRSP
BRSP
ZLAB
ZLAB
Q4 25
-54.6%
Q3 25
-1.7%
-42.3%
Q2 25
-54.5%
-50.3%
Q1 25
5.1%
-53.3%
Q4 24
-24.9%
-62.6%
Q3 24
13.2%
-66.6%
Q2 24
-74.9%
-76.0%
Q1 24
-59.4%
-80.7%
Net Margin
BRSP
BRSP
ZLAB
ZLAB
Q4 25
-17.3%
Q3 25
1.2%
-31.2%
Q2 25
-26.9%
-37.3%
Q1 25
6.9%
-45.8%
Q4 24
-23.7%
Q3 24
14.4%
-40.9%
Q2 24
-74.2%
-80.2%
Q1 24
-59.6%
-61.4%
EPS (diluted)
BRSP
BRSP
ZLAB
ZLAB
Q4 25
$-0.11
$-0.05
Q3 25
$0.00
$-0.03
Q2 25
$-0.19
$-0.04
Q1 25
$0.04
$-0.04
Q4 24
$-0.16
$-0.09
Q3 24
$0.09
$-0.04
Q2 24
$-0.53
$-0.08
Q1 24
$-0.45
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BRSP
BRSP
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$66.8M
$689.6M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$938.4M
$715.5M
Total Assets
$3.6B
$1.2B
Debt / EquityLower = less leverage
2.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BRSP
BRSP
ZLAB
ZLAB
Q4 25
$66.8M
$689.6M
Q3 25
$113.4M
$717.2M
Q2 25
$154.3M
$732.2M
Q1 25
$200.9M
$757.3M
Q4 24
$302.2M
$779.7M
Q3 24
$263.8M
$616.1M
Q2 24
$203.3M
$630.0M
Q1 24
$221.5M
$650.8M
Total Debt
BRSP
BRSP
ZLAB
ZLAB
Q4 25
$2.5B
Q3 25
$2.2B
Q2 25
$2.3B
Q1 25
$2.3B
Q4 24
$2.5B
Q3 24
$2.6B
Q2 24
$2.5B
Q1 24
$2.6B
Stockholders' Equity
BRSP
BRSP
ZLAB
ZLAB
Q4 25
$938.4M
$715.5M
Q3 25
$976.4M
$759.9M
Q2 25
$994.4M
$791.7M
Q1 25
$1.0B
$810.8M
Q4 24
$1.0B
$840.9M
Q3 24
$1.1B
$667.7M
Q2 24
$1.1B
$704.2M
Q1 24
$1.2B
$762.2M
Total Assets
BRSP
BRSP
ZLAB
ZLAB
Q4 25
$3.6B
$1.2B
Q3 25
$3.3B
$1.2B
Q2 25
$3.4B
$1.2B
Q1 25
$3.6B
$1.2B
Q4 24
$3.7B
$1.2B
Q3 24
$3.8B
$985.3M
Q2 24
$3.8B
$987.4M
Q1 24
$3.9B
$988.4M
Debt / Equity
BRSP
BRSP
ZLAB
ZLAB
Q4 25
2.63×
Q3 25
2.22×
Q2 25
2.27×
Q1 25
2.27×
Q4 24
2.38×
Q3 24
2.36×
Q2 24
2.28×
Q1 24
2.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BRSP
BRSP
ZLAB
ZLAB
Operating Cash FlowLast quarter
$73.0M
$-26.0M
Free Cash FlowOCF − Capex
$55.1M
$-26.7M
FCF MarginFCF / Revenue
66.2%
-21.0%
Capex IntensityCapex / Revenue
21.6%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$102.0M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BRSP
BRSP
ZLAB
ZLAB
Q4 25
$73.0M
$-26.0M
Q3 25
$29.9M
$-32.0M
Q2 25
$17.4M
$-31.0M
Q1 25
$10.5M
$-61.7M
Q4 24
$103.4M
$-55.8M
Q3 24
$31.3M
$-26.8M
Q2 24
$22.9M
$-42.2M
Q1 24
$24.6M
$-90.1M
Free Cash Flow
BRSP
BRSP
ZLAB
ZLAB
Q4 25
$55.1M
$-26.7M
Q3 25
$27.4M
$-35.0M
Q2 25
$11.6M
$-33.9M
Q1 25
$8.0M
$-63.2M
Q4 24
$97.3M
$-58.4M
Q3 24
$28.3M
$-28.2M
Q2 24
$22.7M
$-42.9M
Q1 24
$22.2M
$-91.1M
FCF Margin
BRSP
BRSP
ZLAB
ZLAB
Q4 25
66.2%
-21.0%
Q3 25
32.7%
-30.4%
Q2 25
13.4%
-31.1%
Q1 25
10.3%
-59.9%
Q4 24
116.6%
-53.8%
Q3 24
32.1%
-27.7%
Q2 24
24.9%
-42.9%
Q1 24
23.2%
-104.5%
Capex Intensity
BRSP
BRSP
ZLAB
ZLAB
Q4 25
21.6%
0.5%
Q3 25
2.9%
2.6%
Q2 25
6.8%
2.6%
Q1 25
3.2%
1.5%
Q4 24
7.3%
2.4%
Q3 24
3.4%
1.3%
Q2 24
0.1%
0.7%
Q1 24
2.5%
1.1%
Cash Conversion
BRSP
BRSP
ZLAB
ZLAB
Q4 25
Q3 25
30.36×
Q2 25
Q1 25
1.97×
Q4 24
Q3 24
2.46×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BRSP
BRSP

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons